US equities |
NVDA $236.64 ▲+1.15% SPCX $166.61 ▲+4.81% MU $1,067.70 ▼-0.67% TSLA $377.19 ▲+1.78% MSFT $527.34 ▲+1.90% INTC $117.30 ▼-1.70% SNDK $1,732.82 ▲+0.75% META $741.88 ▲+1.90%
FinancialContent

Insmed Incorporated - Common Stock (NQ:INSM)

102.09 -9.03 (-8.13%)
Delayed Quote Updated: 10:21 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insmed Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
3 Healthcare Stocks Showing Why the Sector Still Has Momentum ↗
Oscar Health, Hinge Health, and Insmed post strong earnings and revenue growth in 2026, with analysts projecting further upside despite sector risks like Medicaid cuts and drug pricing pressure. 
Via MarketBeat
Topics Artificial Intelligence Intellectual Property
Insmed (NASDAQ:INSM) Sets Up for Breakout With Strong Technicals ↗
Via Chartmill
News headline image
Here's How Much $100 Invested In Insmed 5 Years Ago Would Be Worth Today ↗
Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 24.42% on an annualized basis producing an average annual return of 35.99%. Currently, Insmed has a market capitalization of... 
Via Benzinga
News headline image
If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today ↗
Insmed (NASDAQ:INSM) has outperformed the market over the past 10 years by 10.74% on an annualized basis producing an average annual return of 24.29%. Currently, Insmed has a market capitalization of... 
Via Benzinga
News headline image
Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal ↗
Duquesne Family Office has beefed up its healthcare holdings. 
Via The Motley Fool
Insmed (NASDAQ:INSM) Q1 Revenue Miss Triggers Pre-Market Slide Despite Narrower Loss ↗
Via Chartmill
News headline image
Insmed (INSM) Q2 2026 Earnings Call Transcript ↗
BRINSUPRI revenue surged to $309.2 million, driving total revenues to $425.5 million. 
Via The Motley Fool
Topics Earnings
News headline image
$1000 Invested In Insmed 5 Years Ago Would Be Worth This Much Today ↗
Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 29.76% on an annualized basis producing an average annual return of 41.43%. Currently, Insmed has a market capitalization of... 
Via Benzinga
News headline image
Insmed Q2 Earnings Call Highlights ↗
Insmed (NASDAQ:INSM) reported second-quarter 2026 revenue growth driven by the continued launch of BRINSUPRI and steady sales of ARIKAYCE, while raising its full-year BRINSUPRI revenue outlook and... 
Via MarketBeat
Topics Earnings
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Which stocks are moving before the opening bell on Thursday? ↗
Via Chartmill
News headline image
What Happens to Stocks After Joining the Nasdaq-100 (History Has a Clear Answer) ↗
SpaceX recently joined the Nasdaq-100 
Via The Motley Fool
Topics Artificial Intelligence Electric Vehicles Initial Public Offering
News headline image
Insmed's TPIP Shows Durable PAH Benefits in 12-Month Study ↗
Insmed (NASDAQ:INSM) reported 12-month results from an ongoing open-label extension study of TPIP in patients with pulmonary arterial hypertension, saying the data showed sustained efficacy measures... 
Via MarketBeat
Monday's after hours session: top gainers and losers ↗
Via Chartmill
Tuesday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
NWI Management Dumps 42,700 MercadoLibre Shares Worth $82.4 Million ↗
MercadoLibre delivers e-commerce and fintech solutions across Latin America, leveraging an integrated digital ecosystem for regional growth. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology. 
Via The Motley Fool
News headline image
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing ↗
This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus ↗
Insmed (NASDAQ:INSM) Chair and CEO Will Lewis said the company remains confident in the launch trajectory of BRINSUPRI, despite investor concerns over discontinuation rates that followed the company’s... 
Via MarketBeat
News headline image
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗
This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials. 
Via The Motley Fool
News headline image
This Nuclear Tech Stock Grew Revenue 27%, But a Fund Still Slashed Its Stake ↗
Mirion Technologies delivers radiation detection and monitoring solutions to healthcare and industrial clients worldwide. 
Via The Motley Fool
Topics Energy Regulatory Compliance
News headline image
This Retail Stock Is Down 10% in a Year Despite Record Revenue. A Fund Just Cut Its Stake ↗
This global retailer offers apparel and accessories across multiple brands and channels in North America, Europe, and Asia. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Trade School Stock Is Up 135%. Here’s Why a Fund Still Bought 459,000 Shares ↗
Lincoln Educational Services delivers hands-on technical and healthcare training across 22 campuses, serving workforce needs nationwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Callaway Stock Has Soared 150%. Here’s Why One Fund Still Bought 1.1 Million Shares ↗
Callaway Golf Company combines branded equipment sales with experiential entertainment through its Topgolf venues and lifestyle offerings. 
Via The Motley Fool
News headline image
Insmed (INSM) Q1 2026 Earnings Transcript ↗
Insmed (INSM) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗
RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗
This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 Next >